Plasma Levels of MK0633 in Children Ages 6-12 (0633-023)

Status:
Completed

Trial end date:
2009-01-01

Target enrollment:

Participant gender:

To evaluate the safety, tolerability and plasma levels of single oral doses of MK0633 in pediatric asthma patients ages 6 to less than 12 years.

Phase 1

Merck Sharp & Dohme Corp.